7.50Open7.50Pre Close0 Volume373 Open Interest260.00Strike Price0.00Turnover38.14%IV5.70%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry7.50Extrinsic Value100Contract SizeAmericanOptions Type0.4107Delta0.0170Gamma39.24Leverage Ratio-0.2304Theta0.0550Rho16.11Eff Leverage0.2338Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet